Efalizumab - Raptiva

February 2009
The European Medicines Agency (EMEA) has recently reviewed Efalizumab (Raptiva) following concerns regarding the long-term safety for patients. The EMEA have recommended that the marketing authorisation should be withdrawn across Europe. Patients currently using Raptiva should make an appointment with their Dermatologist to discuss an alternative treatment, but should not stop Rapitva abruptly.
Patients who have taken Raptiva in the past and have any questions or concerns should make an appointment with their GP or Dermatologist.
For further information, please visit http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/RaptivaQ&A_1552509en.pdf